Today: 19 May 2026
Browse Category

NSE:CASTROLIND 25 December 2025 - 26 December 2025

BP’s $10.1bn Castrol Deal: Stonepeak Buys 65% Stake as Castrol India Open Offer Sets ₹194.04 Price

BP’s $10.1bn Castrol Deal: Stonepeak Buys 65% Stake as Castrol India Open Offer Sets ₹194.04 Price

BP will sell 65% of Castrol to Stonepeak for an enterprise value of $10.1 billion, retaining a 35% stake. Stonepeak and CPPIB must launch an open offer for up to 26% of Castrol India at ₹194.04 per share, a slight premium to recent prices. BP expects $6 billion in net proceeds, aiming to cut debt. The deal is set to close by end-2026, pending approvals.
26 December 2025
····
BP sells 65% of Castrol to Stonepeak in $10.1bn deal as Castrol India open offer follows

BP sells 65% of Castrol to Stonepeak in $10.1bn deal as Castrol India open offer follows

BP will sell a 65% stake in Castrol to Stonepeak, valuing the lubricants business at $10.1 billion. The deal will net BP about $6 billion and leave it with a 35% stake in a new joint venture. CPP Investments will support the transaction with up to $1.05 billion. Closing is expected by the end of 2026, pending regulatory approval.
25 December 2025
····
Castrol India Stock in Focus on 25 Dec 2025: Open Offer at ₹194.04 After BP Sells Castrol Stake to Stonepeak

Castrol India Stock in Focus on 25 Dec 2025: Open Offer at ₹194.04 After BP Sells Castrol Stake to Stonepeak

BP agreed to sell a 65% stake in Castrol to Stonepeak for $10.1 billion, triggering a mandatory open offer for up to 26% of Castrol India at ₹194.04 per share. CPP Investments will invest up to $1.05 billion for an indirect stake. Castrol India shares jumped 9% to ₹202.40 on December 24 after the news. The transaction is expected to close by end-2026, pending regulatory approvals.
25 December 2025
···

Stock Market Today

  • When Will Island Pharmaceuticals Limited (ASX:ILA) Reach Profitability?
    May 19, 2026, 3:26 AM EDT. Island Pharmaceuticals Limited (ASX:ILA), a drug repurposing company focusing on antiviral therapeutics in Australia and the U.S., posted a AU$3.9 million loss in the latest financial year and a AU$7.2 million loss over the trailing twelve months. Analysts project the company will break even in 2027 and reach a profit of AU$295 million by 2028. This forecast implies an ambitious average annual growth rate of 140%. Notably, Island Pharmaceuticals operates with no debt, relying solely on shareholder funding, which reduces financial risk typical in cash-burning pharmaceutical firms. Investors anticipate milestone developments but should remain cautious of the high growth assumptions given the volatile nature of pharmaceutical cash flows during drug development phases.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

IREN Drops Again After AI Cloud Plans Get Costlier

IREN Drops Again After AI Cloud Plans Get Costlier

18 May 2026
IREN shares dropped 7.2% to $49.15 Monday after the company acquired its marketing partner Awaken, folding the agency into its operations. The decline followed IREN’s $3 billion convertible-note sale last week to fund a major data-center expansion for AI services. Quarterly revenue fell and net loss widened as the company shifts from Bitcoin mining to AI cloud infrastructure.
Go toTop